Susan Hilsenbeck | Academic Influence

Susan Hilsenbeck's AcademicInfluence.com Rankings

Susan Hilsenbeck

Mathematics

#6493

World Rank

#8977

Historical Rank

#1953

USA Rank

Applied Mathematics

#225

World Rank

#249

Historical Rank

#68

USA Rank

Statistics

#613

World Rank

#694

Historical Rank

#161

USA Rank

Measure Theory

#1386

World Rank

#1738

Historical Rank

#481

USA Rank

mathematics Degrees

Download Badge

Mathematics

Susan Hilsenbeck's Degrees

Masters Statistics Stanford University
Bachelors Mathematics University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Math 2025

Why Is Susan Hilsenbeck Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Susan Galloway Hilsenbeck is an American biostatistician whose research interests include biomarkers and the applications of biostatistics in cancer research. She is a professor in the Baylor College of Medicine, where she directs the Quantitative Sciences Share Resource in the Dan L. Duncan Comprehensive Cancer Center.

(See a Problem?)

Susan Hilsenbeck's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. (2008) (1796)
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (2009) (1352)
Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer (2014) (850)
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer (2003) (849)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. (2003) (811)
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. (2002) (488)
p53 is mutated in a subset of advanced-stage prostate cancers. (1993) (401)
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis (2012) (391)
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. (2013) (374)
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. (1996) (365)
Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. (2016) (351)
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. (2008) (348)
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. (2013) (347)
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. (1999) (337)
Medical complications and outcomes after hip fracture repair. (2002) (331)
Phase I and pharmacokinetic trial of weekly CPT-11. (1993) (309)
Significance of axillary lymph node metastasis in primary breast cancer. (1999) (279)
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase (2011) (277)
Risk of pulmonary complications after elective abdominal surgery. (1996) (276)
Incidence and hospital stay for cardiac and pulmonary complications after abdominal surgery (1995) (257)
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. (2008) (257)
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. (2006) (248)
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. (2000) (241)
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer (2010) (240)
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers (2005) (239)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation (2011) (233)
Social Networkers' Attitudes Toward Direct-to-Consumer Personal Genome Testing (2009) (231)
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. (2011) (231)
Time-dependence of hazard ratios for prognostic factors in primary breast cancer (2004) (225)
Hippo pathway effector Yap is an ovarian cancer oncogene. (2010) (222)
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. (2013) (219)
Investigation of taxol as a potential radiation sensitizer (1993) (216)
Breast Cancer Patients with Progesterone Receptor PR-A-Rich Tumors Have Poorer Disease-Free Survival Rates (2004) (215)
Postoperative complications after thoracic and major abdominal surgery in patients with and without obstructive lung disease. (1993) (212)
Association of Surgery With Improved Survival in Stage IV Breast Cancer Patients (2008) (210)
Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. (2003) (210)
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. (1999) (205)
Primary breast cancer phenotypes associated with propensity for central nervous system metastases (2006) (199)
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells (2011) (195)
Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. (2005) (192)
Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: correlation with clinical parameters and disease-free survival. (1997) (181)
Thermal Enhancement with Optically Activated Gold Nanoshells Sensitizes Breast Cancer Stem Cells to Radiation Therapy (2010) (176)
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells (2010) (175)
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. (1992) (175)
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia (2007) (174)
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. (1992) (171)
The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. (2002) (167)
Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. (2006) (166)
Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial (2017) (156)
An epigenomic approach to therapy for tamoxifen-resistant breast cancer (2014) (155)
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib (2011) (154)
Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. (2002) (153)
Cigarette Smoke Induction of Osteopontin (SPP1) Mediates TH17 Inflammation in Human and Experimental Emphysema (2012) (149)
Global Effects of Virulence Gene Regulators in a Bacillus anthracis Strain with Both Virulence Plasmids (2003) (144)
Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. (2005) (144)
Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth (2002) (134)
Somatic Mutation of p53 Leads to Estrogen Receptor α-Positive and -Negative Mouse Mammary Tumors with High Frequency of Metastasis (2004) (131)
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients (2008) (130)
Comparison of OG1RF and an Isogenic fsrB Deletion Mutant by Transcriptional Analysis: the Fsr System of Enterococcus faecalis Is More than the Activator of Gelatinase and Serine Protease (2006) (129)
Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells (1992) (129)
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. (2008) (127)
Prognostic factors of early stage cervical cancer treated by radical hysterectomy (1995) (126)
Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. (2009) (125)
Hsp27 overexpression inhibits doxorubicin–induced apoptosis in human breast cancer cells (1999) (123)
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer (2005) (120)
High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy (2010) (119)
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. (2018) (118)
Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. (1995) (116)
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. (1996) (116)
EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells (2017) (116)
Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers (2014) (115)
Global gene expression analysis of estrogen receptor transcription factor cross talk in breast cancer: identification of estrogen-induced/activator protein-1-dependent genes. (2005) (115)
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives (2011) (112)
To share or not to share: A randomized trial of consent for data sharing in genome research (2011) (111)
Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials (2016) (109)
Balancing the Risks and Benefits of Genomic Data Sharing: Genome Research Participants’ Perspectives (2011) (109)
Molecular profiles of progesterone receptor loss in human breast tumors (2009) (108)
Research with stored biological samples: what do research participants want? (2005) (106)
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. (2006) (106)
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer (2016) (106)
atxA Controls Bacillus anthracis Capsule Synthesis via acpA and a Newly Discovered Regulator, acpB (2004) (105)
The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. (1997) (105)
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53 (1997) (102)
GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex (2014) (101)
Practical p-value adjustment for optimally selected cutpoints. (1996) (100)
Cyclopamine inhibition of human breast cancer cell growth independent of Smoothened (Smo) (2009) (100)
STAT3 Signaling Is Activated Preferentially in Tumor‐Initiating Cells in Claudin‐Low Models of Human Breast Cancer (2014) (98)
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance (2006) (97)
Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: detection of higher levels in tumors with poor prognostic features. (1996) (95)
Multiple splicing variants of the estrogen receptor are present in individual human breast tumors (1996) (93)
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. (2003) (92)
Hazard rates of recurrence following diagnosis of primary breast cancer (2004) (91)
Microinvasive carcinoma of the cervix (1992) (91)
The prognostic significance of surgical staging for carcinoma of the endometrium. (1992) (91)
Survival after first recurrence of breast cancer. The miami experience (1992) (90)
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. (2016) (88)
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth (2004) (87)
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. (2004) (87)
Laparoscopic cholecystectomy and cirrhosis: A case‐control study of outcomes (2000) (86)
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. (1998) (85)
Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer (2009) (85)
Molecular Heterogeneity of Inflammatory Breast Cancer: A Hyperproliferative Phenotype (2006) (83)
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. (2019) (83)
Fibroblast Growth Factor Receptor Signaling Is Essential for Normal Mammary Gland Development and Stem Cell Function (2013) (83)
Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments. (2004) (82)
Why do so many prognostic factors fail to pan out? (2005) (82)
Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. (2011) (81)
cFos is critical for MCF-7 breast cancer cell growth (2005) (80)
Recombinant insulin‐like growth factor binding protein‐1 inhibits IGF‐I, serum, and estrogen‐dependent growth of MCF‐7 human breast cancer cells (1993) (80)
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy (2015) (79)
Heat shock proteins and drug resistance (2004) (79)
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer (2017) (79)
Congenital Anomalies and Anthropometry of 42 Individuals with Deletions of Chromosome 18q (1999) (78)
Prevalence of Cryptosporidium parvum infection in children along the Texas-Mexico border and associated risk factors. (2000) (75)
Modernizing Eligibility Criteria for Molecularly Driven Trials. (2015) (74)
Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. (1998) (73)
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. (2016) (72)
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. (2000) (72)
Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization (aCGH): revealing significant overlapping genomic lesions with diffuse large B-cell lymphoma (2009) (70)
Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model (2012) (70)
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. (1999) (69)
GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells. (2009) (69)
A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: clinical outcomes and development of fluconazole resistance. (1998) (68)
Role of the Estrogen Receptor Coactivator AIB 1 ( SRC-3 ) and HER-2 / neu in Tamoxifen Resistance in Breast Cancer (2003) (68)
Tacrolimus clearance is age-dependent within the pediatric population (2000) (68)
Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. (1988) (66)
Evidence That an Early Pregnancy Causes a Persistent Decrease in the Number of Functional Mammary Epithelial Stem Cells—Implications for Pregnancy‐Induced Protection Against Breast Cancer (2008) (66)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (66)
Effects of TP53 mutational status on gene expression patterns across 10 human cancer types (2014) (64)
Agonistic induction of PPARγ reverses cigarette smoke-induced emphysema. (2014) (63)
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer (2018) (63)
Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency (2013) (63)
The prognostic significance of surgical staging for carcinoma of the endometrium (1993) (63)
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome (2012) (62)
Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. (2015) (62)
The SOX11 transcription factor is a critical regulator of basal-like breast cancer growth, invasion, and basal-like gene expression (2016) (62)
Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients (2014) (61)
Preclinical and clinical strategies for development of telomerase and telomere inhibitors. (1997) (61)
AACR Cancer Progress Report 2014 (2014) (60)
Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor–Positive Breast Cancer (2006) (60)
Igf system components as prognostic markers in breast cancer (1998) (60)
Assessment of the learning curve for pancreaticoduodenectomy. (2012) (59)
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. (1994) (59)
Cross-species identification of a plasma microRNA signature for detection, therapeutic monitoring, and prognosis in osteosarcoma (2015) (59)
AP-1 blockade inhibits the growth of normal and malignant breast cells (2001) (59)
Accuracy of CT in predicting malignant potential of cystic pancreatic neoplasms. (2008) (58)
Value of pancreatic resection for cancer metastatic to the pancreas. (2010) (57)
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies (2005) (57)
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. (1996) (57)
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis (2015) (56)
Association between the Estrogen Receptor α A908G Mutation and Outcomes in Invasive Breast Cancer (2007) (56)
Association Between Birth Defects and Cancer Risk Among Children and Adolescents in a Population-Based Assessment of 10 Million Live Births. (2019) (56)
Congenital anomalies and anthropometry of 42 individuals with deletions of chromosome 18q. (1999) (55)
cDNA expression arrays reveal incomplete reversal of age-related changes in gene expression by calorie restriction (2000) (55)
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer (2015) (55)
CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT (2016) (54)
Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. (1997) (54)
The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention. (2005) (54)
Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. (2010) (54)
Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors (2011) (53)
A demonstration that breast cancer recurrence can be predicted by Neural Network analysis (2005) (53)
Transcriptional Profiling of Mammary Gland Side Population Cells (2006) (52)
Effect of BioGlue® on the Incidence of Pancreatic Fistula Following Pancreas Resection (2008) (50)
Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. (2009) (50)
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. (2011) (50)
Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression. (1994) (49)
Early exposure of the rat mammary gland to estrogen and progesterone blocks co-localization of estrogen receptor expression and proliferation. (2001) (49)
Mechanisms of Hormonal Prevention of Breast Cancer (2001) (48)
Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer. (1997) (48)
Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. (2017) (48)
Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions (2018) (48)
Value of pancreatic resection for cancer metastatic to the pancreas. (2008) (48)
Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer (2011) (47)
The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor–Negative Tumors in MMTV-erbB2 Mice (2007) (47)
Identification of biomarkers modulated by the rexinoid LGD1069 (bexarotene) in human breast cells using oligonucleotide arrays. (2006) (46)
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay (1999) (46)
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea (1998) (46)
Progesterone Receptor Isoform-Specific Promoter Methylation: Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients (2011) (44)
Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth (2012) (44)
Participants' Recall and Understanding of Genomic Research and Large-Scale Data Sharing (2013) (43)
Rising levels of estrogen receptor in breast cancer over 2 decades. (1994) (42)
Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. (1993) (42)
Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer. (1994) (41)
The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways (2019) (41)
Semaphorin 4F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer (2013) (40)
Carbon nanotube capsules enhance the in vivo efficacy of cisplatin. (2017) (40)
Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy (2013) (40)
Drain data to predict clinically relevant pancreatic fistula. (2010) (40)
Improved methods of estimating mitotic activity in solid tumors. (1992) (39)
The epidemiology of viral hepatitis in children in South Texas: increased prevalence of hepatitis A along the Texas-Mexico border. (1999) (39)
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer (2013) (39)
The AP-1 transcription factor regulates postnatal mammary gland development. (2006) (39)
Chemoprevention of BBN-Induced Bladder Carcinogenesis by the Selective Estrogen Receptor Modulator Tamoxifen. (2013) (39)
Differential regulation of cell cycle characteristics and apoptosis in MMTV-myc and MMTV-ras mouse mammary tumors. (1997) (39)
Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. (2001) (38)
Detection of insulin-like growth factor binding proteins (IGFBPs) by ligand blotting in breast cancer tissues. (1994) (38)
Low SAFB levels are associated with worse outcome in breast cancer patients (2010) (38)
Sp1 is essential for estrogen receptor α gene transcription (2002) (38)
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers (2011) (37)
Rising levels of estrogen receptor in breast cancer over 2 decades (1994) (37)
Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer. (2020) (37)
Genomic approaches in the management and treatment of breast cancer (2005) (37)
Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma (2020) (36)
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance (2016) (36)
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance (2018) (36)
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer (2018) (36)
Ablation of steroid receptor coactivator-3 resembles the human CACT metabolic myopathy. (2012) (35)
Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. (2015) (35)
Preoperative spirometry and laparotomy: blowing away dollars. (1997) (34)
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. (1998) (34)
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. (2005) (34)
Gene expression in Barrett's esophagus: Laser capture versus whole tissue (2009) (34)
Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. (1995) (33)
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer (2019) (33)
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer (2011) (33)
Pediatric Data Sharing in Genomic Research: Attitudes and Preferences of Parents (2014) (32)
Prognostic Factors in Lung Cancer Based on Multivariate Analysis (1993) (32)
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. (1999) (31)
Array-based gene expression profiling to study aging (2001) (31)
The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways (2018) (31)
Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. (1990) (30)
Making sense of clinical trial data: is inverse probability of censoring weighted analysis the answer to crossover bias? (2012) (30)
Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. (2001) (30)
Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients (1997) (29)
Research Resource: Roles for Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) in Systems Metabolism. (2016) (29)
Model-Assisted Designs for Early-Phase Clinical Trials: Simplicity Meets Superiority. (2019) (29)
P190B RhoGAP has pro-tumorigenic functions during MMTV-Neu mammary tumorigenesis and metastasis (2010) (29)
Synergistic effects of taxol/taxotere on radiation sensitivity on human tumor cell lines (1992) (28)
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer (2010) (28)
Prevention of Hypovolemic Circulatory Collapse by IL-6 Activated Stat3 (2008) (28)
Sp1 is essential for estrogen receptor alpha gene transcription. (2002) (28)
HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. (2016) (28)
Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers (2005) (28)
p53 mutation and tamoxifen resistance in breast cancer. (1995) (28)
Expression of ERG protein in prostate cancer: variability and biological correlates. (2015) (28)
Amplification and over‐expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells (2014) (27)
The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer (2009) (27)
Optimal mastectomy timing. (1992) (27)
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. (2000) (27)
The promise of microarrays in the management and treatment of breast cancer (2005) (26)
Research resource: tissue- and pathway-specific metabolomic profiles of the steroid receptor coactivator (SRC) family. (2013) (26)
Activity of 2, 2 -difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units (1992) (26)
Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer (2015) (26)
Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes. (2018) (26)
Preoperative prediction of complete resection in pancreatic cancer. (2008) (25)
Isolation of the ocular surface to treat dysfunctional tear syndrome associated with computer use. (2007) (25)
Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. (1990) (25)
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
Conditional overexpression of Stat3α in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro‐oncogenic gene expression pattern (2007) (25)
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (2019) (25)
WAF1/CIP1 protein expression in human breast tumors (1997) (24)
Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. (2010) (24)
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
Targeting the Activator Protein 1 Transcription Factor for the Prevention of Estrogen Receptor–Negative Mammary Tumors (2008) (23)
Segmental mastectomy without radiotherapy for T1 and small T2 breast carcinomas. (1990) (23)
The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. (2014) (23)
Estimation of completeness and adjustment of age-specific and age-standardized incidence rates. (1992) (23)
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion (2016) (23)
Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression (2009) (22)
Prevention of Trauma/Hemorrhagic Shock‐Induced Lung Apoptosis by IL‐6‐Mediated Activation of Stat3 (2009) (21)
Lung Carcinoma in 1,336 Patients (1991) (21)
Apoptosis in the murine rd1 retinal degeneration is predominantly p53-independent. (1998) (20)
Biomarkers in benign breast disease: risk factors for breast cancer. (1998) (20)
Clinical trial of high‐dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature (1988) (19)
Prognostic factors: Rationale and methods of analysis and integration (2004) (18)
Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence (2012) (18)
Predictors of post-mastectomy reconstruction in an underserved population. (2013) (17)
Measure once or twice -- does it really matter? (1999) (17)
Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft (1999) (17)
The p160 ER co-regulators predict outcome in ER negative breast cancer (2011) (17)
The Increasing Recognition of Adenosquamous Lung Carcinoma (1977–1986) (1992) (17)
An essential role for Gαi2 in Smoothened-stimulated epithelial cell proliferation in the mammary gland (2015) (16)
MGI 114: augmentation of antitumor activity when combined with topotecan. (2000) (16)
p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos (2004) (15)
Wnt-1 is Dominant over Neu in Specifying Mammary Tumor Expression Profiles (2006) (15)
Preclinical activity of ilmofosine against human tumor colony forming units in vitro (1992) (15)
HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials. (2018) (14)
Prevention of Tumorigenesis in p53-Null Mammary Epithelium by Rexinoid Bexarotene, Tyrosine Kinase Inhibitor Gefitinib, and Celecoxib (2009) (14)
Toxicity of FED Chemotherapy in Non‐small‐Cell Lung Cancer (1987) (13)
Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor‐Induced Arthralgias: An Analysis of CCTG MA.27 (2018) (13)
Effect of Selective Ablation of Proliferating Mammary Epithelial Cells on MNU Induced Rat Mammary Tumorigenesis (2002) (13)
Is There a Role for Adjuvant Tamoxifen in Progesterone Receptor–Positive Breast Cancer? An In silico Clinical Trial (2006) (13)
Immunofluorescence Microscopy and Flow Cytometry Characterization of Chemical Induction of Latent Epstein-Barr Virus (1998) (13)
Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis (2014) (13)
Proinsulin‐producing, hyperglycemia‐induced adipose tissue macrophages underlie insulin resistance in high fat‐fed diabetic mice (2015) (13)
Quality control practices in centralized tumor registries in North America. (1990) (13)
Early termination of a phase II clinical trial. (1988) (13)
Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice (2018) (13)
Lack of prognostic value of cathepsin D levels for predicting short term outcomes of breast cancer patients. (1997) (13)
Hypothyroidism after craniospinal irradiation with proton or photon therapy in patients with medulloblastoma (2018) (12)
NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. (2017) (12)
Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (12)
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer (2004) (12)
A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities (2018) (12)
POSITIVELY AGING: CHOICES AND CHANGES CREATING INTERDISCIPLINARY MIDDLE SCHOOL TEACHING MATERIALS USING EXAMPLES FROM GERIATRICS AND GERONTOLOGY (1999) (11)
Treatment of murine hepatic metastases with vaccinia colon oncolysates and IL-2. (1988) (11)
A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. (2015) (11)
Comparative efficacy of short‐term versus long‐term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: A prospective study (1991) (11)
A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis (2011) (11)
Effects of Recombinant Human Interleukin‐1α on Clonogenic Growth of Primary Human Tumors In Vitro (1992) (10)
The role of single nucleotide polymorphisms in breast cancer metastasis (2008) (10)
Defining the role of raloxifene for the prevention of breast cancer. (2004) (10)
Inhibition of the p 38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells (2009) (10)
Cancer among haitians in Florida (1987) (10)
Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells (2015) (9)
Hormonal Modulation of ESR1 Mutant Metastasis (2020) (9)
Human Tumor Screening (2004) (9)
Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia (2019) (9)
In vitro and in vivo magnetic resonance imaging (MRI) detection of GFP through magnetization transfer contrast (MTC) (2010) (9)
Advances in Brief A Hypersensitive Estrogen Receptor-a Mutation in Premalignant Breast Lesions 1 (2000) (9)
Surrogate endpoints in chemoprevention of breast cancer: Guidelines for evaluation of new biomarkers (1993) (8)
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. (1999) (8)
Exome sequencing disclosures in pediatric cancer care: Patterns of communication among oncologists, genetic counselors, and parents. (2018) (8)
Making the most of your prognostic factors: Presenting a more accurate survival model for breast cancer patients (2005) (8)
Krt6a-Positive Mammary Epithelial Progenitors Are Not at Increased Vulnerability to Tumorigenesis Initiated by ErbB2 (2015) (7)
Abstract CN04-04: Phase II trial of bexarotene in women at high risk of breast cancer: Comparison of protein and RNA biomarkers (2008) (7)
The Status of STAT3 and STAT5 in Human Breast Atypical Ductal Hyperplasia (2015) (7)
Stereotactic Biopsy of Segmental Breast Calcifications: Is Sampling of Anterior and Posterior Components Necessary? (2016) (6)
Comparison of three tumor markers — CA‐125, lipid‐associated sialic acid (LSA), and NB/70K — in monitoring ovarian cancer (1991) (6)
Mouse‐INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy (2021) (6)
Five-drug antiemetic combination for cisplatin chemotherapy. (1992) (6)
BRCA1 promoter methylation status does not predict response to tamoxifen in sporadic breast cancer patients (2012) (6)
A Wnt-Independent LGR4–EGFR Signaling Axis in Cancer Metastasis (2021) (6)
Pharmacogenetics of Breast Cancer: Toward the Individualization of Therapy (2009) (6)
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
In vitro activity of the benzotriazine dioxide SR 4233 against human tumour colony-forming units. (1993) (6)
Decrease in tumorigenic breast cancer stem cells – final results of a neoadjuvant trial in primary breast cancer patients (2008) (5)
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression (2020) (5)
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement (2006) (5)
Publisher Correction: EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells (2018) (5)
A phase I/II study combining a TMZ-CD40L/4-1BBL-armed oncolytic adenovirus and nab-paclitaxel/gemcitabine chemotherapy in advanced pancreatic cancer: An interim report. (2020) (5)
Genomic approaches to understanding and treating breast cancer. (2004) (5)
Does formal instruction about the BI-RADS ultrasound lexicon result in improved appropriate use of the lexicon? (2013) (5)
Mutation and Tamoxifen Resistance in Breast Cancer ’ (2005) (5)
Abstract 3091: A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis (2012) (5)
Outcomes Among Minority Patients With Metastatic Colorectal Cancer in a Safety-net Health Care System. (2020) (5)
Scalp cooling alopecia prevention trial (SCALP) for patients with early stage breast cancer. (2016) (4)
Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
A Network Approach to Identify Biomarkers of Differential Chemotherapy Response Using Patient-Derived Xenografts of Triple-Negative Breast Cancer (2021) (4)
Correction: Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model (2012) (4)
Advances in Brief The Retinoid X Receptor-Selective Retinoid , LGD 1069 , Prevents the Development of Estrogen Receptor-Negative Mammary Tumors in Transgenic Mice 1 (2002) (4)
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity (2020) (4)
Food of Silvery Grebes (Podiceps occipitalis) at Lake Cuicocha, Ecuador (1979) (3)
Advances in Brief The Small Heat Shock Protein hsp 27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines 1 (2007) (3)
Title : HER 2 signaling drives DNA anabolism and proliferation through SRC-3 phosphorylation and E 2 F 1-regulated genes (2016) (3)
Correction: Prevention of Hypovolemic Circulatory Collapse by IL-6 Activated Stat3 (2008) (3)
Acquisition and use of information on data quality in large population-based tumor registries (1990) (3)
Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium (2022) (3)
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression (2020) (3)
Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics (2021) (3)
Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach (2022) (3)
Targeting the Pro-survival Protein BCL-2 to Prevent Breast Cancer (2021) (3)
Apoptosis in the Murine rd 1 Retinal Degeneration is Predominantly p 53-Independent (1998) (3)
A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
Molecular biology (pre-clinical) (2012) (3)
The Rexinoid LG 100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor ^ NegativeTumors in MMTV-erbB 2 Mice (2007) (3)
PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery (2022) (3)
Intratumoral heterogeneity in a p53 null mouse model of human breast cancer (2015) (3)
Abstract S4-03: Identification of a notch-driven breast cancer stem cell gene signature for anti-notch therapy in an ER+ presurgical window model (2015) (3)
A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop (2021) (3)
What’s in an exome? Diversity of diagnostic and incidental findings revealed by clinical tumor and germline sequencing of 100 children with solid tumors. (2014) (2)
Implications for Molecular-Based Chemoprevention Breast Cells through Transcription Factor Crosstalk : Down-regulates Cyclooxygenase-2 Expression in Human The Retinoid X Receptor-Selective Retinoid , LGD 1069 (2005) (2)
Long-term survival in stage III and IV ovarian cancer (2006) (2)
Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts (2021) (2)
Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients (2014) (2)
Abstract IA16: Clinical genomics for children with solid tumors: Current realities and future opportunities (2016) (2)
Value of 8S/4S fractionation of estrogen receptors (ER) for prediction of response to hormonal manipulation in metastatic breast cancer (1984) (2)
Semaphorin 4 F as a Critical Regulator of Neuroepithelial Interactions and a Biomarker of Aggressive Prostate Cancer (2013) (2)
Elevated Expression of MAPK Phosphatase 3 in Breast Tumors—A Mechanism of Tamoxifen Resistance (2006) (2)
BRCA1 in clinical breast cancer. (1998) (2)
Abstract 856: High expression of DUSP4 in ER-negative breast cancer cells suppresses growth and invasion. (2013) (2)
Abstract P6-13-04: Metformin for the treatment of ductal carcinoma in situ (DCIS) (2015) (2)
Abstract IA16: Evaluating the implementation and utility of clinical tumor exome sequencing in the pediatric oncology clinic: Early results of the BASIC3 study (2014) (2)
Mailed Self-Sample HPV Testing Kits to Improve Cervical Cancer Screening in a Safety Net Health System: Protocol for a Hybrid Type 2 Randomized Effectiveness-Implementation Trial (2020) (1)
Endoscopic assessment of radiological stage IVA cervical cancer: A bivariate meta-analysis supporting an evidence-based staging algorithm proposal. (2022) (1)
A phase I and pharmacokinetic trial of terephthalamidine (NSC 57155) as a 120-hour continuous infusion (1998) (1)
Utility of screening for hepatocellular carcinoma among cirrhotics (2011) (1)
Estrogen priming before progestin therapy in advanced breast cancer (1990) (1)
Unique Breast Cancer Features Within the Vietnamese Population (2016) (1)
39A Incorporating toxicity grade information in the continual reassessment method for phase I cancer clinical trials (1995) (1)
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome (2012) (1)
Abstract 11: Evaluating cancer susceptibility mutations and incidental findings from whole exome sequencing of sequentially diagnosed pediatric solid and brain tumor patients: Early results of the BASIC3 study (2014) (1)
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models (2021) (1)
Abstract B04: Identification of molecular predictors of differential chemotherapy response using patient-derived xenografts (2016) (1)
Implementation and evaluation of clinical exome sequencing in childhood cancer care: The BASIC3 study. (2013) (1)
Commentary The promise of microarrays in the management and treatment of breast cancer (2005) (1)
Abstract 971: Phosphatase PTP4A3 is critical for cell growth of triple-negative breast cancer (2014) (1)
Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells (2015) (1)
Subtype of Breast Tumor Xenografts Transforms the Clinically Associated Molecular Profile Development of Resistance to Targeted Therapies (2008) (1)
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
Abstract 1814: NF1 as an estrogen receptor-α co-repressor in breast cancer (2018) (1)
Reply to Bonnefoix and Callanan: Significance of Akt/Wnt pathway in radiation resistance of TICs (2010) (1)
Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8 (2015) (1)
Selected abstracts submitted to the Third International Symposium on Hereditary Breast and Ovarian Cancer (2009) (1)
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models (2021) (1)
LBA-19 PHASE II TRIAL OF ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER WITH TAMOXIFEN (2019) (1)
Mailed self-sample HPV testing kits to improve cervical cancer screening in a safety net health system: protocol for a hybrid effectiveness-implementation randomized controlled trial (2020) (1)
Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer (2015) (1)
Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC). (2016) (1)
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance (2018) (1)
Non-nuclear human estrogen receptor-alpha 36 (hERα-36) is expressed in ER, PR, and Her2 positive or negative breast cancer patients as well as cell lines, and physically interacts with Her2 (2008) (1)
A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. (2022) (1)
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (1)
Abstract 1664: Maternal embryonic leucine aipper kinase (MELK) is a critical regulator of proliferation and is independently prognostic in estrogen receptor-negative breast cancer (2011) (1)
Scalp cooling alopecia prevention trial (SCALP). (2014) (1)
Abstract 4862: Autocrine secreted IL-6 and IL-8 play critical and non-redundant roles in basal-like breast cancer cell transformation and growthin vitroandin vivo (2012) (1)
Abstract No. 481 Visualization performance of neuroangiographic systems using a novel calibrated dynamic vascular phantom: a comparison of Philips Allura and Siemens Artis Zeego (2018) (0)
Gene expression profiles in formalin-fixed, paraffin-embedded (FFPE) core biopsies predict docetaxel chemosensitivity. (2006) (0)
Pitfalls in the RNA-based PCR amplification of the CDRIII sequence for quantitation of minimal residual disease in multiple myeloma (Commentary). (1997) (0)
Abstract 2290: Crosstalk between ER and PI3K signaling pathways in human luminal type breast cancer and its therapeutic implications (2011) (0)
Abstract 4132: Expression of pattern recognition receptor genes and survival in colorectal adenocarcinoma (2014) (0)
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer: Experience from a safety-net hospital serving a racially and ethnically diverse patient population. (2023) (0)
Abstract P2-09-09: Genetic assessment of hereditary breast and ovarian cancer in the Smith Clinic: A 10-year, single center experience (2022) (0)
Breast tumor xenografts of luminal subtype switch to the ERBB2+ molecular subtype in response to endocrine therapy: Gene expression profiling may not predict pathways of resistance in pretreatment tumors (2007) (0)
Sensitizes Breast Cancer Stem Cells to Radiation Therapy Thermal Enhancement with Optically Activated Gold Nanoshells (2010) (0)
Is Mutated in a Subset of Advanced-Stage Prostate Cancers 1 (2006) (0)
Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells (2015) (0)
Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positivein vivobreast cancer models (2019) (0)
Predictive Biomarkers and Personalized Medicine Progesterone Receptor Isoform-Specific Promoter Methylation : Association of PRA Promoter Methylation with Worse Outcome in Breast Cancer Patients (2011) (0)
Abstract 738: Combined inhibition of non-canonical HER2 signaling as a strategy to overcome resistance to HER2-targeted therapies (2015) (0)
Gene Expression Profiling of Node-Negative Breast Tumors Reveals Metastatic Recurrence Risk (2004) (0)
Genetic assessment of hereditary breast and ovarian cancer in the Harris Health System: A five-year, single-center experience. (2021) (0)
Abstract LB-121: DAXX is a novel Notch-1 gene target and biomarker of GSI-sensitivity in ER+ breast cancer (2016) (0)
AWARD NUMBER: W81XWH-14-1-0326 TITLE: Overcoming Endocrine Resistance by Targeting ER/FoxA1/IL-8 Axis PRINCIPAL INVESTIGATOR: Xiaoyong Fu CONTRACTING ORGANIZATION: Baylor College of Medicine (2016) (0)
Resource : Roles for Calcium / Calmodulin-Dependent Protein Kinase Kinase 2 ( CaMKK 2 ) in Systems Metabolism (2016) (0)
What Does Susan Hilsenbeck Do When She Is Not Being a Statistician (2017) (0)
Abstract 3124: Identification of transcription factors critical for the growth of basal-like breast cancer. (2013) (0)
ComprehensiveGenomicAnalysis Identi fi esNovel Subtypes and Targets of Triple-Negative Breast Cancer (2015) (0)
Abstract P6-11-01: A broad spectrum therapeutic strategy for TNBC revealed by a new pathway that coordinates oncogenic RTKs (2015) (0)
Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models (2015) (0)
EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells (2017) (0)
Molecular and Cellular Pathobiology Cancer Research Fibroblast Growth Factor Receptor Signaling Dramatically Accelerates Tumorigenesis and Enhances Oncoprotein Translation in the Mouse Mammary Tumor Virus – Wnt-1 Mouse Model of Breast Cancer (2010) (0)
Author response: Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy (2013) (0)
Role of adenomatous polyposis coli (APC) gene in SPOP-mutant prostate cancer and clinical outcomes. (2023) (0)
TBIO-20. CLINICAL TUMOR WHOLE EXOME SEQUENCING FOR PEDIATRIC NEURO-ONCOLOGY PATIENTS – RESULTS FROM THE BAYLOR ADVANCING SEQUENCING IN CHILDHOOD CANCER CARE (BASIC3) CLINICAL SEQUENCING STUDY (2018) (0)
STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential (2022) (0)
Abstract 5278: Circulating microRNAs profile as a novel biomarker for osteosarcoma. (2013) (0)
Tumors Apoptosis in MMTV-myc and MMTV-ras Mouse Mammary Differential Regulation of Cell Cycle Characteristics and Updated Version (2006) (0)
3488 A comparison between the Rolling 6 and 3+3 dose escalation study designs for phase 1 clinical trials (2019) (0)
BCM PDX Portal: An Intuitive Web-based Tool for Patient-Derived Xenograft Collection Management, as well as Visual Integration of Clinical and Omics Data (2023) (0)
Abstract B58: CELF1 is a central node in post-transcriptional regulatory programs underlying EMT and metastasis in breast epithelial cells (2016) (0)
Abstract A54: Combining the rexinoid bexarotene with tamoxifen to prevent ER‐negative mammary tumors in MMTV‐erbB2 mice (2010) (0)
Abstract 5169: Diagnostic yield of clinical tumor and germline exome sequencing for newly diagnosed children with solid tumors (2014) (0)
Abstract 1223: Evaluation of the dual p38/NLK kinase inhibitor as potential new therapeutic agent for tamoxifen-resistant breast cancer (2017) (0)
Abstract P2-12-22: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense adriamycin/cyclophosphamide in locally advanced triple negative breast cancer: A single-center real-world experience (2022) (0)
Abstract 5193: Identification of molecular predictors of differential chemotherapy response using patient-derived xenografts (2016) (0)
Retrospective review of genomic testing in breast cancer: Does it improve outcome? (2017) (0)
Abstract 2139: Wild type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL8 secretion via JAK2 activation (2015) (0)
Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis (2015) (0)
Abstract 2296: Identification of novel nuclear receptor targets in estrogen receptor negative breast cancer (2011) (0)
Blockade of the AP-1 transcription factor prevents wnt1-induced, but not c-myc-induced mammary tumors in mice (2007) (0)
Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer (2023) (0)
Abstract 1665: Targeting phosphatases for the treatment of ER-negative breast cancer (2011) (0)
Patient education intervention to improve diversity in breast cancer clinical trials. (2022) (0)
Abstract P2-08-14: Effect of markers of systemic inflammation on tumor infiltrating lymphocytes in patients with non-metastatic triple negative and HER2+ breast cancer: A single center retrospective study (2022) (0)
Abstract 3470: Obesity and metformin alter progression of triple negative breast cancer (2016) (0)
Abstract 2913: The SOX11 transcription factor is critical for basal-like breast cancer growth and migration and is associated with poor survival (2016) (0)
Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance (2015) (0)
Abstract A42: Autocrine-produced IL-6 and IL-8 are essential for the growth and maintenance of the transformed phenotype of basal-like breast cancer cells (2011) (0)
Patient education intervention to improve breast cancer clinical trials participation. (2022) (0)
S44 The Incidence of Cholangiocarcinoma Among Primary Sclerosing Cholangitis Patients Is Lower Than Previously Reported (2022) (0)
Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense adriamycin/cyclophosphamide in locally advanced triple negative breast cancer: A single-center experience in a safety net hospital. (2021) (0)
Abstract 282: FGF receptor signaling accelerates Wnt-1 mammary tumorigenesis and enhances translation of Wnt/β-catenin target oncogenes (2010) (0)
Abstract 2857: Induced expression of DUSP4 and PPM1A in ER-negative breast cancer cells suppresses proliferation and invasion (2012) (0)
Abstract P2-01-13: Longitudinal circulating tumor DNA (ctDNA) monitoring by digital droplet PCR (ddPCR) in metastatic breast cancer (2022) (0)
Combining Atovaquone with Intensive Conventional Chemotherapy for Pediatric Acute Myeloid Leukemia (AML) Is Feasible and Well Tolerated (2021) (0)
Human Cancer Biology Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor – Negative Breast Cancer (2009) (0)
197 : Long-Term Follow-up of Low Grade Astrocytomas in Children - The Texas Childrens Hospital Experience (2006) (0)
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer (2021) (0)
Clinical and biological factors associated with central nervous system metastases in breast cancer (2007) (0)
Utility of microarrays in the management of breast cancer patients (2005) (0)
Gene signature of cancer stem cells is manifested within an intrinsic subgroup of breast cancers with mesenchymal properties (2008) (0)
Vitamin D and aromatase inhibitor-induced arthralgia: Analysis of Canadian cancer trial group MA.27 data. (2016) (0)
Abstract 1996: Identification of four subgroups of Triple Negative Breast Cancer (TNBC) by genomic profiling. (2013) (0)
ASSESSING THE UTILITY OF CLINICAL TUMOR SEQUENCING IN THE PEDIATRIC NEURO-ONCOLOGY CLINIC (2014) (0)
Abstract 2992: Proteogenomic characterization of triple-negative breast cancer patient-derived xenografts reveals molecular correlates of differential chemotherapy response and potential therapeutic targets to overcome resistance (2021) (0)
Clonal Evolution of the HER2 L755S Mutation Leads to Acquired HER‐targeted Therapy Resistance That Can Be Reversed by the Irreversible HER1/2 Inhibitor Afatinib (2015) (0)
p53-Mediated Oxidative Stress and Apoptosis (2004) (0)
The Small Heat Shock Protein hsp27 Is Correlated with Growth and Drug Resistance in Human Breast Cancer Cell Lines 1 (2007) (0)
Abstract P1-07-07: Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers (2015) (0)
Abstract PD3-07: A phase II pre-surgical trial of lapatinib for the treatment of women with HER2 positive or EGFR positive ductal carcinoma in situ (2019) (0)
Epidemiology of Cryptosporidium parvum in Three Groups of Children in South Texas (1999) (0)
Advances in Brief Differential Regulation of Cell Cycle Characteristics and Apoptosis in MMTV-myc and MMTV-ras Mouse Mammary Tumors ' (2006) (0)
Viewpoint The role of single nucleotide polymorphisms in breast cancer (2008) (0)
Overexpression of Stat3α, but Not Statβ, in Myeloid Cells Results in Neutrophil Expansion through Reduced Apoptosis and Modulation of a Unique Set of Apoptosis Pathway Genes. (2006) (0)
Significance o f A xillary L ymph N ode M etastasis in P rimary B reast C ancer (1999) (0)
Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy (2019) (0)
Contents Volume 16, 1998 (2004) (0)
Abstract 105: PREDICTORS OF POST-MASTECTOMY RECONSTRUCTION IN AN UNDERSERVED POPULATION (2013) (0)
Preoperativ ePredictio no fComplet eResectio ni nPancreati cCancer (2008) (0)
Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency (2013) (0)
Abstract 2853: Discovery of phosphatases that regulate growth and tumorigenicity of ER-negative breast cancers (2012) (0)
Abstract P4-15-05: Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2-negative (HER2-) breast cancer (PACT01 trial) (2019) (0)
Abstract P5-07-01: Proteogenomic analysis of differential chemotherapy responses in patient-derived xenografts of triple-negative breast cancer (2022) (0)
Abstract P2-23-01: Patient-derived xenografts allow deconvolution of single agent and combination chemotherapy responses in triple-negative breast cancer (2023) (0)
Overcoming Endocrine Resistance by Targeting ER/FoxA1/IL 8 Axis (2015) (0)
The MAPK inhibitor, MKP3, is an estrogen receptor α coactivator associated with tamoxifen resistance (2005) (0)
EDITORIALS Biomarkers in Benign Breast Disease: Risk Factors for Breast Cancer (1998) (0)
AP-1 blockade in vivo suppresses development of mammary tumor im MMTV- erbB2 mice (2006) (0)
Abstract 3299: Maternal embryonic leucine zipper kinase is critical for the growth and migration of triple negative breast cancer cells (2014) (0)
Response to the Letter by Smith et al. (2009) (0)
Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial. (2022) (0)
Abstract LB-106: Expression of stem cell biomarkers in benign breast tissue from patients with triple negative breast cancer (2011) (0)
Correction to: Hormonal modulation of ESR1 mutant metastasis (2021) (0)
Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment (2022) (0)
Abstract 1467: Feasibility and relevance of “animal clinical trials” using breast cancer patient-derived xenografts (PDX) in mice (2015) (0)
Abstract 4133: Comparative gene expression and proteomic analysis of IGF-I and insulin signaling in a large panel of breast cancer cell lines (2010) (0)
Abstract B43: A preponderance of post-menopausal HER2+ breast cancer in the Vietnamese population (2016) (0)
Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated (2023) (0)
HG-49A TEXAS-OKLAHOMA PEDIATRIC NEURO-ONCOLOGY CONSORTIUM (TOPNOC) PHASE 2 STUDY OF VALPROIC ACID (VPA) AND RADIATION, FOLLOWED BY MAINTENANCE VPA AND BEVACIZUMAB IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) OR HIGH-GRADE GLIOMAS (HGG). (2016) (0)
Abstract 04: Impact of whole exome sequencing results on clinical decision making for pediatric solid tumor patients in the hypothetical scenario of tumor relapse: A survey of pediatric oncologists (2016) (0)
Change in management based on actionable mutations in metastatic breast cancer in an ethnically diverse cohort: Single institution experience. (2021) (0)
The Effects of Artificial Tears and Micro-Envirmoment Glasses (MEGSTM) on Evaporative Dry Eye Ocular Surface Signs and Symptoms in Computer Vision Syndrome (2007) (0)
Abstract IA15: Development of Novel Models and Identification of Therapeutic Vulnerabilities in Highly Aggressive Prostate Cancer In African American Men (2020) (0)
Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients. (2008) (0)

This paper list is powered by the following services:

Other Resources About Susan Hilsenbeck

en.wikipedia.org

What Schools Are Affiliated With Susan Hilsenbeck?

Susan Hilsenbeck is affiliated with the following schools: